1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Aerie Misses Quick Path To Dry Eye Approval, But Is Still Moving Forward

After Failing Phase IIb Study, Company Adds Phase III Trial

 
• By Joseph Haas

AR-15512 missed the primary endpoints in a Phase IIb dry eye disease study that could have served as a pivotal trial, but Aerie’s drug hit enough signs and symptoms of the disease to justify a Phase III.

Render illustration of Clinical Trial title on medical documents
Disappointing results from a Phase IIb study don't forestall Aerie's plans in dry eye

Shareholders remain unhappy with Aerie Pharmaceuticals, Inc.’s attempt to spin a failed Phase IIb study for its TRMP8 agonist AR-11512 in dry eye disease as a success. But since multiple endpoints were hit in the trial, the company is planning to move ahead with two Phase III trials and could still obtain US approval in an increasingly crowded therapeutic space.

Right after market closing on 15 September, Aerie announced that the 369-patient COMET-1 study of AR-15512 missed the predetermined primary...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D

Actuate Is Looking For A Buyer To Advance Pancreatic Cancer Candidate

 
• By Jessica Merrill

After presenting encouraging Phase II data on the GSK-3 inhibitor elraglusib at ASCO, Actuate Therapeutics is hoping to hold a pre-NDA meeting with the US FDA.

In Brief: Kezar Plots Lupus Revival For Zetomipzomib As FDA Lifts Hold On Hepatitis Trial

 
• By Manas Mishra

The go-ahead to resume a trial for its only drug candidate, zetomipzomib, in hepatitis could give Kezar a glimmer of hope of reviving another halted study in lupus nephritis.

AstraZeneca’s Amyloidosis Drug Fails In Phase III But Subgroup Hopes Persist

 
• By Andrew McConaghie

Anselamimab was expected to complement Alexion's portfolio of amyloid therapies, but regulators will have to be convinced of its benefits to a patient subgroup in the CARES trial.